AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation ...Middle East

TAIPEI, June 22, 2026 /PRNewswire/ -- AnHorn Medicines today announced that its lead neuroprotective candidate AH-008, being developed for the prevention of chemotherapy-induced peripheral neuropathy (CIPN), has achieved two major regulatory milestones: Investigational New Drug (IND)...

Hence then, the article about ah 008 achieves dual regulatory milestones with u s fda ind clearance and taiwan cde index case designation was published today ( Tuesday 23/06/2026 - 03:01 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( AH-008 Achieves Dual Regulatory Milestones with U.S. FDA IND Clearance and Taiwan CDE Index Case Designation )

Also on site :

• You're Probably Wasting $200 a Month on These Sneaky Bills
• Lucid Motors’ new CEO cuts 18% of staff to ‘simplify the company’
• SDG&E kickstarts process to set future rates — and City Council votes to back state bills to rein in utility costs